Literature DB >> 7619670

Halofantrine pharmacokinetics in Kenyan children with non-severe and severe malaria.

W M Watkins1, P A Winstanley, E K Mberu, G Kokwaro, S A Murphy, C J Newton, I Mwangi, D Forster, K Marsh.   

Abstract

1. Kenyan children with uncomplicated malaria given oral halofantrine (HF; non-micronised suspension; 8 mg base kg-1 body weight 6 hourly for three doses) showed wide variation in the disposition of HF and desbutylhalofantrine (HFm). 2. Eight Kenyan children with severe (prostrate) falciparum malaria who were receiving intravenous quinine, were given the same HF regimen by nasogastric tube. One patient had undetectable HF and two had undetectable HFm at all times after drug administration. 3. The mean AUC(0,24 h) of HF in prostrate children was half (7.54 compared with 13.10 micrograms ml-1 h) (P = 0.06), and that for HFm one-third (0.84 compared with 2.51 micrograms ml-1 h) (P < 0.05) of the value in children with uncomplicated malaria. 4. Oral HF may be appropriate for some cases of uncomplicated falciparum malaria in Africa, but in patients with severe malaria, the bioavailability of HF and HFm may be inadequate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7619670      PMCID: PMC1365005          DOI: 10.1111/j.1365-2125.1995.tb04450.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Reduced in vitro susceptibility to halofantrine of Plasmodium falciparum in West Africa.

Authors:  P Ringwald; J LeBras; C Voyer; J P Coulaud
Journal:  Lancet       Date:  1990-02-17       Impact factor: 79.321

2.  Pharmacokinetics of halofantrine in man: effects of food and dose size.

Authors:  K A Milton; G Edwards; S A Ward; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

3.  Cardiac effect of halofantrine.

Authors:  J Karbwang; K Na Bangchang; D Bunnag; T Harinasuta; P Laothavorn
Journal:  Lancet       Date:  1993-08-21       Impact factor: 79.321

4.  Cardiac effects of antimalarial treatment with halofantrine.

Authors:  F Nosten; F O ter Kuile; C Luxemburger; C Woodrow; D E Kyle; T Chongsuphajaisiddhi; N J White
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

5.  Fast emergence of Plasmodium falciparum resistance to halofantrine.

Authors:  P Brasseur; P Bitsindou; R S Moyou; T A Eggelte; G Samba; L Penchenier; P Druilhe
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

6.  Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations.

Authors:  N J White; K D Miller; F C Churchill; C Berry; J Brown; S B Williams; B M Greenwood
Journal:  N Engl J Med       Date:  1988-12-08       Impact factor: 91.245

7.  Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria.

Authors:  J Karbwang; K A Milton; K Na Bangchang; S A Ward; G Edwards; D Bunnag
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

8.  The pathophysiology of severe falciparum malaria.

Authors:  R E Phillips; D A Warrell
Journal:  Parasitol Today       Date:  1986-10

9.  Measurement of halofantrine and its major metabolite desbutylhalofantrine in plasma and blood by high-performance liquid chromatography: a new methodology.

Authors:  E K Mberu; D K Muhia; W M Watkins
Journal:  J Chromatogr       Date:  1992-10-02

10.  Efficacy of multiple-dose halofantrine in treatment of chloroquine-resistant falciparum malaria in children in Kenya.

Authors:  W M Watkins; J A Oloo; J D Lury; M Mosoba; D Kariuki; M Mjomba; D K Koech; H M Gilles
Journal:  Lancet       Date:  1988-07-30       Impact factor: 79.321

View more
  4 in total

1.  Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.

Authors:  D R Abernethy; D L Wesche; J T Barbey; C Ohrt; S Mohanty; J C Pezzullo; B G Schuster
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

2.  Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria.

Authors:  Te-Yu Hung; Timothy M E Davis; Kenneth F Ilett; Harin Karunajeewa; Sean Hewitt; Mey Bouth Denis; Chiv Lim; Doung Socheat
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

3.  Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods.

Authors:  Iftekhar Mahmood; Anna Cheng; Edward Brauer; Rita Humeniuk
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

Review 4.  Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base.

Authors:  Olivier Bouchaud; Patrick Imbert; Jean Etienne Touze; Alex N O Dodoo; Martin Danis; Fabrice Legros
Journal:  Malar J       Date:  2009-12-10       Impact factor: 2.979

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.